Addex Therapeutics Ltd (ADXN)

Switzerland
Currency in CHF
0.058
+0.002(+3.57%)
Closed·
ADXN Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected in 7 days
Fair Value
Day's Range
0.0550.058
52 wk Range
0.0470.110
Key Statistics
Edit
Bid/Ask
0.06 / 0.059
Prev. Close
0.058
Open
0.058
Day's Range
0.055-0.058
52 wk Range
0.047-0.11
Volume
15.33K
Average Vol. (3m)
247.64K
1-Year Change
-20.55%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ADXN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
0.160
Upside
+175.86%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year
Show more

Addex Therapeutics Ltd Company Profile

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson’s disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The Charcot–Marie–Tooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.

Compare ADXN to Peers and Sector

Metrics to compare
ADXN
Peers
Sector
Relationship
P/E Ratio
−0.4x13.6x−0.5x
PEG Ratio
0.000.000.00
Price / Book
0.5x2.9x2.6x
Price / LTM Sales
9.6x2.5x2.9x
Upside (Analyst Target)
175.9%58.0%53.4%
Fair Value Upside
Unlock3.6%10.2%Unlock

Analyst Ratings

0 Buy
0 Hold
2 Sell
Ratings:
2 analysts
Overall Consensus
Sell

Analysts 12-Month Price Target:

Average 0.160
(+175.86% Upside)

Earnings

Latest Release
Apr 25, 2025
EPS / Forecast
-- / -0.01
Revenue / Forecast
-- / 200.00K
EPS Revisions
Last 90 days

FAQ

What Is the Addex Therapeutics Ltd (ADXN) Stock Price Today?

The Addex Therapeutics Ltd stock price today is 0.06

What Stock Exchange Does Addex Therapeutics Ltd Trade On?

Addex Therapeutics Ltd is listed and trades on the Switzerland Stock Exchange stock exchange.

What Is the Stock Symbol for Addex Therapeutics Ltd?

The stock symbol for Addex Therapeutics Ltd is "ADXN."

What Is the Addex Therapeutics Ltd Market Cap?

As of today, Addex Therapeutics Ltd market cap is 5.70M.

What Is Addex Therapeutics Ltd's Earnings Per Share (TTM)?

The Addex Therapeutics Ltd EPS (TTM) is -0.13.

When Is the Next Addex Therapeutics Ltd Earnings Date?

Addex Therapeutics Ltd will release its next earnings report on May 19, 2025.

From a Technical Analysis Perspective, Is ADXN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.